Piper Sandler Maintains Neutral on Fulgent Genetics, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Westenberg maintains a Neutral rating on Fulgent Genetics (FLGT) and lowers the price target from $28 to $25.
March 06, 2024 | 2:31 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Piper Sandler maintains a Neutral rating on Fulgent Genetics and lowers the price target from $28 to $25.
The reduction in the price target by Piper Sandler could lead to a negative short-term sentiment among investors, potentially causing a decrease in FLGT's stock price. The Neutral rating suggests no significant positive catalysts in the near term to counterbalance the lowered price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100